Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

BACKGROUND: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate‐to‐severe chronic plaque psoria...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Dermatol
Main Authors: Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig, L., Bachelez, H., Chouela, E., Imafuku, S., Thaçi, D., Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2018
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379291/
https://ncbi.nlm.nih.gov/pubmed/30188571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.17149
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker